Skintelligence

Company Overview

Snapshot

Founded in April 2018 by Miriam Oron and Guy Shalom, Skintelligence operated with 1–10 employees. The company secured a grant from the Israel Innovation Authority in December 2018, a key milestone in its early development.

Business overview

Skintelligence developed clinical decision support systems (CDSSs) leveraging artificial intelligence to predict individual responses to biological therapy, particularly for autoimmune diseases like psoriasis, rheumatoid arthritis, and Crohn's disease. The company's core technology, SmartPAD, integrated non-invasive immunologic biomarker measurements from the skin with clinical data to calculate treatment success probabilities. This solution aimed to reduce the trial-and-error process in prescribing biological medications, thereby lowering costs and patient discomfort. Skintelligence operated within the Digital Health and Medical Technologies sector, targeting pharmaceutical companies, clinics, and insurance providers.

Company Intelligence Q&A

What is Skintelligence's primary focus?

Skintelligence develops clinical decision support systems (CDSSs) designed to predict individual responses to biological therapy for autoimmune diseases, aiming to optimize treatment selection and reduce trial-and-error.

When was Skintelligence founded and by whom?

Skintelligence was founded in April 2018 by Miriam Oron and Guy Shalom.

What is SmartPAD?

SmartPAD (SMART Predictor for Autoimmune Diseases) is Skintelligence's patented device that measures immunologic biomarkers from the skin using non-invasive assays and integrates this data with clinical information to predict treatment success with biological drugs.

What was the company's operational status as of December 2021?

Skintelligence ceased to operate in December 2021.

Did Skintelligence receive any grants?

In December 2018, Skintelligence secured a grant from the Israel Innovation Authority.